Lisa A Hammond

Summary

Affiliation: Cancer Therapy and Research Center
Country: USA

Publications

  1. ncbi request reprint Pharmacokinetic evaluation of gefitinib when administered with chemotherapy
    Lisa A Hammond
    Institute for Drug Development, Cancer Therapy Research Center, San Antonio, TX, USA
    Clin Lung Cancer 5:S18-21. 2003
  2. ncbi request reprint Positron emission tomography (PET): expanding the horizons of oncology drug development
    Lisa A Hammond
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Invest New Drugs 21:309-40. 2003
  3. ncbi request reprint Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 12:7406-13. 2006
  4. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
  5. doi request reprint Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
  6. ncbi request reprint A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 13:532-9. 2007
  7. ncbi request reprint A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties
    Samira Syed
    Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:6512-21. 2004
  8. ncbi request reprint Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies
    Quincy Siu Chung Chu
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:4913-21. 2004
  9. ncbi request reprint A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies
    Bahram Forouzesh
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:5540-9. 2003
  10. ncbi request reprint A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:4761-71. 2003

Collaborators

Detail Information

Publications35

  1. ncbi request reprint Pharmacokinetic evaluation of gefitinib when administered with chemotherapy
    Lisa A Hammond
    Institute for Drug Development, Cancer Therapy Research Center, San Antonio, TX, USA
    Clin Lung Cancer 5:S18-21. 2003
    ..The addition of gefitinib to these chemotherapy regimens was generally well tolerated, and there was no apparent increase in higher-grade toxicity. Additional trials are evaluating gefitinib treatment in combination with chemotherapy...
  2. ncbi request reprint Positron emission tomography (PET): expanding the horizons of oncology drug development
    Lisa A Hammond
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Invest New Drugs 21:309-40. 2003
    ..The progress to date and the challenges of incorporating PET technology into oncology drug development from the preclinical to clinical setting are reviewed in this article...
  3. ncbi request reprint Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 12:7406-13. 2006
    ....
  4. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired renal function...
  5. doi request reprint Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
    Jordi Rodon
    Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 62:911-9. 2008
    ..This provided the rationale for the three-times weekly treatment explored in this protocol...
  6. ncbi request reprint A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 13:532-9. 2007
    ..The study also sought to detect major pharmacokinetic drug-drug interactions between these agents and preliminary evidence of antitumor activity in patients with advanced solid malignancies...
  7. ncbi request reprint A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties
    Samira Syed
    Institute for Drug Development, Cancer Therapy and Research Center and University Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:6512-21. 2004
    ..The study also sought to characterize the pharmacokinetic behavior of Col-3 and seek evidence of anticancer activity...
  8. ncbi request reprint Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies
    Quincy Siu Chung Chu
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:4913-21. 2004
    ....
  9. ncbi request reprint A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies
    Bahram Forouzesh
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:5540-9. 2003
    ..The study also sought to determine the maximum tolerated dose (MTD) of ILX-295501 on this schedule, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  10. ncbi request reprint A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:4761-71. 2003
    ..The study also sought to identify drug-drug pharmacokinetic interactions, evaluate effects on protein farnesylation, and seek preliminary evidence for clinical activity...
  11. ncbi request reprint A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies
    Mitchell A Garrison
    Brooke Army Medical Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2527-37. 2003
    ..The MTD was defined for both minimally pretreated (MP) and heavily pretreated (HP) patients as the highest dose level at which the incidence of dose-limiting toxicity does not exceed 20%...
  12. ncbi request reprint Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio 78229, USA
    Clin Cancer Res 12:5207-15. 2006
    ..v. infusion weekly for 3 weeks every 4 weeks...
  13. ncbi request reprint A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma
    Monica M Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    Cancer Chemother Pharmacol 59:165-74. 2007
    ....
  14. ncbi request reprint Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors
    Alejandro D Ricart
    Institute for Drug Development, Cancer Therapy and Research Center, and Department of Pharmacology, University of Texas Health Science Center at San Antonio 78229, USA
    Clin Cancer Res 11:8728-36. 2005
    ..Major toxicologic and pharmacologic differences between the two sequences of drug administration were also assessed...
  15. ncbi request reprint ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA
    Clin Cancer Res 10:7555-65. 2004
    ....
  16. ncbi request reprint A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies
    Lillian L Siu
    Cancer Therapy and Research Center, Institute for Drug Development, San Antonio, Texas 78229, USA
    Clin Cancer Res 8:2157-66. 2002
    ..v. infusion daily for 5 days every 3 weeks in patients with advanced cancer...
  17. ncbi request reprint Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 21:211-22. 2003
    ..v.) once every 3 weeks and to seek evidence of antitumor activity...
  18. ncbi request reprint Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA
    J Clin Oncol 24:2052-8. 2006
    ....
  19. ncbi request reprint Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients
    Shazli N Malik
    The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 9:2478-86. 2003
    ..This study evaluated the pharmacodynamic effects of OSI-774 in normal skin tissues collected from patients treated with the agent in a Phase I study...
  20. ncbi request reprint A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer
    Anthony W Tolcher
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, Texas 78229, USA
    Clin Cancer Res 10:5048-57. 2004
    ....
  21. ncbi request reprint Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study
    Emiliano Calvo
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 10:7112-20. 2004
    ....
  22. ncbi request reprint A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor
    Desiree Hao
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Clin Cancer Res 9:2465-71. 2003
    ..The purpose of this study was to assess the feasibility and characterize the pharmacokinetics of squalamine administered as a continuous i.v. infusion daily for 5 days every 3 weeks...
  23. ncbi request reprint A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies
    Amita Patnaik
    Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, Texas 78229, USA
    Clin Cancer Res 8:2142-8. 2002
    ..Additional disease-directed clinical evaluations of AN-9 are necessary to establish the breadth of its antitumor activity and to assess its role as an effective differentiating agent...
  24. ncbi request reprint A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies
    Eric K Rowinsky
    Institute for Drug Development, Cancer Therapy, and Research Center, San Antonio, TX, USA
    J Clin Oncol 21:148-57. 2003
    ..The study also sought to determine the maximum-tolerated dose (MTD) of PEG-CPT, characterize its pharmacokinetic behavior, and seek preliminary evidence of anticancer activity...
  25. ncbi request reprint A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms
    Lisa A Hammond
    Cancer Therapy and Research Center, University of San Antonio Health Science Center at San Antonio, San Antonio, Texas, USA
    Clin Cancer Res 10:1645-56. 2004
    ....
  26. ncbi request reprint An image worth a thousand lives?
    Lisa A Hammond
    ILEX Products, San Antonio, Texas 78229, USA
    Nat Biotechnol 22:677-8. 2004
  27. ncbi request reprint Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
    Johann S de Bono
    Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 8122 Datapoint Drive, Suite 700, San Antonio, TX 78229, USA
    J Clin Oncol 20:96-109. 2002
    ..To assess the feasibility of administering troxacitabine, a unique L-nucleoside that is not a substrate for deoxycytidine deaminase-mediated catabolism, as a 30-minute intravenous (IV) infusion daily for 5 days...
  28. ncbi request reprint Acute retinal toxicity from the novel anti-tumor agent, Irofulven
    Robert F Melendez
    Department of Ophthalmology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Doc Ophthalmol 108:249-51. 2004
  29. ncbi request reprint A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors
    Scot Ebbinghaus
    Arizona Cancer Center, University of Arizona, Tucson, USA
    Clin Cancer Res 11:7807-16. 2005
    ..To determine the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of the dolastatin-15 analogue, tasidotin (ILX651), when administered i.v. daily for 5 days every 3 weeks...
  30. ncbi request reprint HER-targeted tyrosine-kinase inhibitors
    Jose Baselga
    Medical Oncology Service, Hospital General, Universitari Vall d Hebron, Pg Vall d Hebron 199 129, E 08035 Barcelona, Spain
    Oncology 63:6-16. 2002
    ..Early data show that they are generally well tolerated and have provided evidence of antitumor activity. HER-TK inhibitors are exciting agents that are likely to have a substantial impact on the way we treat patients with cancer...
  31. ncbi request reprint Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction
    Larry J Schaaf
    Clinical Treatment Unit, The Ohio State University Comprehensive Cancer Center, 1248 James Cancer Hospital, 300 West 10th Avenue, Columbus, 43210, USA
    Clin Cancer Res 12:3782-91. 2006
    ..To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule...
  32. ncbi request reprint A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology and Biostatistics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 9:4108-15. 2003
    ....
  33. ncbi request reprint ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
    Malcolm Ranson
    Christie Hospital and Royal Eye Hospital, Manchester, United Kingdom
    J Clin Oncol 20:2240-50. 2002
    ..To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors...
  34. ncbi request reprint Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
    Casey Cunningham
    Tyler Cancer Center, Texas, USA
    Clin Cancer Res 11:7825-33. 2005
    ..To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors...
  35. ncbi request reprint Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer
    Roman Perez-Soler
    Department of Oncology, Montefiore Medical Center Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY 10467, USA
    J Clin Oncol 22:3238-47. 2004
    ..This phase II study of erlotinib in patients with HER1/EGFR-expressing non-small-cell lung cancer previously treated with platinum-based chemotherapy evaluated tumor response, survival, and symptom improvement...